An ongoing dialogue on HIV/AIDS, infectious diseases,
4 Responses to “M184V: So many options, but does that include TDF/FTC/EFV?”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock April 24, 2026In children with septic shock, no significant difference was seen in the incidence of death, new renal-replacement therapy, or persistent kidney dysfunction with balanced fluid as compared with 0.9% saline for fluid resuscitation.
- Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients April 23, 2026In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
- Tuberculosis Cases and Deaths Averted by PEPFAR April 23, 2026Tuberculosis remains a leading cause of death worldwide among persons with HIV. In this report, the effect of the PEPFAR program on incident cases of tuberculosis and related deaths is presented.
- Case 12-2026: An 86-Year-Old Woman with Anorexia, Weight Loss, and Liver Lesions April 23, 2026An 86-year-old woman with a history of diabetes and breast cancer was admitted to the hospital with anorexia and weight loss. Imaging revealed multifocal liver lesions. A diagnosis was made.
- Same Pill, Different Impact — Reassessing the Efficacy of Nirmatrelvir–Ritonavir April 23, 2026The first cases of Covid-19 were reported at the end of 2019, and from January 20, 2020, to May 5, 2023, Covid-19 was considered to be a public health emergency of international concern. The total number of cases worldwide exceeded 1 million by early April 2020. In the United States,...
- Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock April 24, 2026
What about treating her once daily with Atripla + Ziagen —
Would adding abacavir give her the necessary “third drug” in this case and allow her to use Atripla as she desires?
Would the 184V affect the efficacy of the abacavir too much to make it worthwhile?
I would check the hl b 5701 and the trofle assay. If the b 5701 was negative, I would offer her atripla and ziagen. If positive, I would explore twice-daily regimens with her, including isentress, intelence and selzentry as possibilities.
I like Dr. Gallant’s response of ritonavir-boosted PI with tenofovir/FTC even with the M184V. However, instead of a “two-drug regimen,” I would call it a “two and 1/2 drug regimen,” and it makes a lot of sense to me. Perhaps more patients could benefit from this simple regimen.
I would urge the patient to restart therapy using a boosted protease inhibitor based regimen that would be simple (once a day) and relatively fat friendly (such as ritonavir/fosamprenavir or ritonavir/atazanavir or ritonavir/darunavir + Truvada or Epzicom -the latter if HLA B5701 negative). I would be tempted (if the patient was willing) to initially recommend use of another agent (such as raltegravir) to rapidly suppress HIV RNA levels to the detection level and then stop it out of concern about the presence of more extensive NRTI resistance than detected by the genotypic results available and not wanting to use potential monotherapy (just a boosted PI) in a treatment experienced patient with underlying NRTI resistance.